The findings from this study highlight the significant role that immune markers, such as FOXP3, PD-1, and CD32B, play in the tumor microenvironment (TME) of lung adenocarcinoma, providing valuable insights into their potential as prognostic biomarkers and therapeutic targets. This evidence concerns the gene PDCD1 and lung adenocarcinoma.